Management of ACS

The Management of acute coronary syndromes page has been updated following the recent publication of the Australian Heart Foundation 2016 Guidelines on ACS. Chew, DP, Scott, IA, Cullen, L, et al. National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the management of acute coronary syndromes 2016. Med … Read more

Risk stratification of suspected ACS

The Risk stratification of ACS page has been updated following the recent publication of the Australian Heart Foundation 2016 Guidelines on ACS. Chew, DP, Scott, IA, Cullen, L, et al. National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the management of acute coronary syndromes 2016. Med … Read more

JVP

The Cardiovascular examination page has been revised with additional information about the JVP including how 8cm (not 5cm) should be added to the height above the manubriosternal angle to estimate CVP.

Troponin rise after 30 Km run

The Non ACS causes of elevated troponins has been modified to include additional information about the almost universal finding of elevated hsTroponins following a 30km run in well trained individuals. Klinkenberg, LJ, Luyten, P, van der Linden, N, et al. Cardiac Troponin T and I Release After a 30-km Run. Am J Cardiol 2016 . … Read more

Silent MI

The Clinical assessment of suspected ACS page has been updated with additional information about the incidence of silent ischaemia. Incidence and Prognostic Significance of Silent Myocardial Infarction in the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2016;133(22):2141-8.

Non fasting lipids are OK

The Cardiovascular risk reduction page has been updated with the recommendation that fasting for lipid sampling is no longer required. Mora, S. Nonfasting for routine lipid testing: From evidence to action. JAMA Internal Medicine 2016.  

Single value hsTnI rule out strategy

The Troponins in ACS page has been updated with some additional information about single value hsTnI to rule out ACS. The bottom line is that hsTnT is probably more sensitive than hsTnI for clinically significantly outcomes, so is currently preferred. Carlton, E, Greenslade, J, Cullen, L, et al. Evaluation of High-Sensitivity Cardiac Troponin I Levels … Read more

hsTnI 1 hour rule out strategy

The Risk stratification in suspected ACS page has been updated, including information about the use of a hsTnI 1 hour rapid ACS diagnostic pathway. The proposed pathway appears to be not as useful as similar hsTnT pathways. Neumann, JT, Sörensen, NA, Schwemer, T, et al. Diagnosis of Myocardial Infarction Using a High-Sensitivity Troponin I 1-Hour … Read more

Pre PCI beta blockers

The Management of acute coronary syndromes page has been updated with additional information about the role of pre-PCI beta blockers. Roolvink, V, Ibanez, B, Ottervanger, JP, et al. Early Administration of intravenous Beta blockers in patients with ST-elevation myocardial infarction before primary PCI. Journal of the American College of Cardiology 2016.

Myoglobin in ACS

The Other cardiac biomarkers page has been updated with additional information about the role of myoglobin in excluding ACS in low risk patients. Meek, R, Braitberg, G, Cullen, L, et al. Outcome at 30 days for low-risk chest pain patients assessed using an accelerated diagnostic pathway in the emergency department. Emerg Med Australas 2016.